Last reviewed · How we verify

NCT00143429

Corneal Versus Conjunctival Delivery Using a Delivery Device

Withdrawn Phase 2 Last updated 2 February 2021
What this trial tests

Phase 2 trial testing Xalatan in Glaucoma, Open-Angle. Withdrawn.

Quick facts

Lead sponsorPfizer's Upjohn has merged with Mylan to form Viatris Inc.
PhasePhase 2
StatusWithdrawn
Study typeINTERVENTIONAL
Allocationrandomized
Designcrossover
Maskingsingle
Primary purposetreatment

Drugs / interventions tested

Conditions studied

Sponsor

Pfizer's Upjohn has merged with Mylan to form Viatris Inc. — full company profile →

Who can join

18 and older, any sex, with Glaucoma, Open-Angle or Ocular Hypertension. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Compare the antihypertensive efficacy of three methods for installing Xalatan

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other trials of Xalatan

Trials testing the same drug.

Other recruiting trials for Glaucoma, Open-Angle

Currently open trials in the same condition.

Other Pfizer's Upjohn has merged with Mylan to form Viatris Inc. trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT00143429.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing